Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer

Purpose The prevalence and clinical relevance of TP53 and PIK3CA mutations in pretreatment breast cancer have been previously reported. However, little is known regarding these mutations in residual tumor tissues after neoadjuvant chemotherapy. Here, we investigated the association between TP53 and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of cancer research and clinical oncology 2019-05, Vol.145 (5), p.1235-1242
Hauptverfasser:	Chen, Xinyi, Guo, Yonghai, Ouyang, Tao, Li, Jinfeng, Wang, Tianfeng, Fan, Zhaoqing, Fan, Tie, Lin, Benyao, Xu, Ye, Xie, Yuntao
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers, Tumor Biopsy Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - mortality Breast Neoplasms - pathology Cancer Research Chemotherapy Chemotherapy, Adjuvant Class I Phosphatidylinositol 3-Kinases - genetics Female Hematology Humans Internal Medicine Kaplan-Meier Estimate Medical prognosis Medicine Medicine & Public Health Middle Aged Mutation Neoplasm Grading Neoplasm Staging Oncology Original Article – Cancer Research p53 Protein Progesterone Prognosis Survival Treatment Outcome Tumor Burden Tumor Suppressor Protein p53 - genetics Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!